Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016


  • Products Id :- GMDHC0525TDB
  • |
  • Pages: 58
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016', provides in depth analysis on Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted pipeline therapeutics.

The report provides comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)

- The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects

- The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Overview 7

Therapeutics Development 8

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Stage of Development 8

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Therapy Area 9

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Indication 10

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Companies 13

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Universities/Institutes 15

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 20

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development 21

Amgen Inc. 21

Bristol-Myers Squibb Company 22

Chong Kun Dang Pharmaceutical Corp. 23

Japan Tobacco Inc. 24

Kowa Company, Ltd. 25

Merck & Co., Inc. 26

Pfizer Inc. 27

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles 28

AMG-899 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

anacetrapib - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BMS-795311 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CKD-519 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

dalcetrapib - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

HL-16 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

K-312 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

PF-04445597 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Projects 41

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products 42

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Featured News & Press Releases 45

Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial 45

Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics 45

Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial 46

Nov 13, 2015: Merck Provides Update on REVEAL Outcomes Study 48

Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery 48

Jun 03, 2015: Dezima Pharma's CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet 49

Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease 50

Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels 50

Aug 29, 2014: Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia 51

Jul 08, 2014: Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995 52

Jan 13, 2014: Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995 52

Aug 29, 2013: Dezima Pharma initiates Phase 2b TULIP study on CETP inhibitor program DEZ-001 53

Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds 54

Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program 55

May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib 55

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 20

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Amgen Inc., H2 2016 21

Pipeline by Bristol-Myers Squibb Company, H2 2016 22

Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 23

Pipeline by Japan Tobacco Inc., H2 2016 24

Pipeline by Kowa Company, Ltd., H2 2016 25

Pipeline by Merck & Co., Inc., H2 2016 26

Pipeline by Pfizer Inc., H2 2016 27

Dormant Projects, H2 2016 41

Discontinued Products, H2 2016 42

Discontinued Products (Contd..1), H2 2016 43

Discontinued Products (Contd..2), H2 2016 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

Bristol-Myers Squibb Company

Chong Kun Dang Pharmaceutical Corp.

Japan Tobacco Inc.

Kowa Company, Ltd.

Merck & Co., Inc.

Pfizer Inc.

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Therapeutic Products under Development, Key Players in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Therapeutics, Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Pipeline Overview, Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Pipeline, Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Pipeline Assessment

select a license

Single User License
USD 3500 INR 226030
Site License
USD 7000 INR 452060
Corporate User License
USD 10500 INR 678090

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com